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Utilization of biopsy-based genomic classifier to predict distant
metastasis after definitive radiation and short-course ADT for
intermediate and high-risk prostate cancer
PL Nguyen1, NE Martin1, V Choeurng2, B Palmer-Aronsten2, T Kolisnik2, CJ Beard1, PF Orio1, MD Nezolosky1, Y-W Chen1, H Shin2,
E Davicioni2 and FY Feng3
BACKGROUND:We examined the ability of a biopsy-based 22-marker genomic classifier (GC) to predict for distant metastases after
radiation and a median of 6 months of androgen deprivation therapy (ADT).
METHODS: We studied 100 patients with intermediate-risk (55%) and high-risk (45%) prostate cancer who received definitive
radiation plus a median of 6 months of ADT (range 3–39 months) from 2001–2013 at a single center and had available biopsy
tissue. Six to ten 4 micron sections of the needle biopsy core with the highest Gleason score and percentage of tumor involvement
were macrodissected for RNA extraction. GC scores (range, 0.04–0.92) were determined. The primary end point of the study was
time to distant metastasis. Median follow-up was 5.1 years. There were 18 metastases during the study period.
RESULTS: On univariable analysis (UVA), each 0.1 unit increase in GC score was significantly associated with time to distant
metastasis (hazard ratio: 1.40 (1.10–1.84), P= 0.006) and remained significant after adjusting for clinical variables on multivariable
analysis (MVA) (adjusted hazard ratio: 1.36 (1.04–1.83), P= 0.024). The c-index for 5-year distant metastasis was 0.45 (95%
confidence interval: 0.27–0.64) for Cancer of the Prostate Risk Assessment score, 0.63 (0.40–0.78) for National Comprehensive
Cancer Network (NCCN) risk groups, and 0.76 (0.57–0.89) for the GC score. Using pre-specified GC risk categories, the cumulative
incidence of metastasis for GC40.6 reached 20% at 5 years after radiation (P= 0.02).
CONCLUSIONS: We believe this is the first demonstration of the ability of the biopsy-based GC score to predict for distant
metastases after definitive radiation and ADT for intermediate- and high-risk prostate cancer. Patients with the highest GC risk
(GC40.6) had high rates of metastasis despite multi-modal therapy suggesting that they could potentially be candidates for
treatment intensification and/or enrollment in clinical trials of novel therapy.
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INTRODUCTION
Radiation and androgen deprivation therapy (ADT) is a standard
therapy for contemporary patients with intermediate and high-risk
prostate cancer.1 While many men will be cured with this
treatment, there remains a proportion of men who will progress
after therapy and develop metastatic disease. For these men,
intensification of therapy beyond standard duration ADT and
radiation may be required to further reduce the risk of metastasis.
Because intensification of therapy using longer durations of
ADT, second-generation anti-androgens, chemotherapy or novel
agents carries risk of additional toxicity, it is critically important to
correctly identify the subgroup of patients who may be in need of
such intensification. While clinical factors such as PSA, T-category
and Gleason score have traditionally been used to risk-stratify
patients, their accuracy has been significantly enhanced in the last
few years by genomic-based tests. However, most genomic tests
for prostate cancer have been discovered or validated in either the
post-prostatectomy setting or more recently the active surveil-
lance setting, and it remains unknown whether they can predict
for a clinically meaningful end point such as distant metastasis
after definitive radiation and ADT.
For example, the Oncotype Dx test from Genomic Health is used
on biopsy tissue from National Comprehensive Cancer Network
(NCCN) very low through intermediate risk prostate cancer and
gives the risk of harboring adverse pathology (pT3 or Gleason ⩾ 4
+3) at prostatectomy.2 The Prolaris test from Myriad Genetics can
predict 10-year prostate cancer specific mortality with conserva-
tive management from biopsy tissue or biochemical recurrence
from radical prostatectomy tissue.3 Finally, the Decipher test from
GenomeDx Biosciences can be used on both biopsy and
prostatectomy specimens to predict the risk of distant metastasis
after prostatectomy.4–6
In this study, we examined whether the biopsy-based 22-gene
Decipher genomic classifier (GC) can be used to accurately predict
for the risk of distant metastasis in a contemporary cohort with
both intermediate and high-risk prostate cancer who all received
radiation and ADT.
MATERIALS AND METHODS
Patient selection and treatment
Our initial cohort included 153 patients who received radiation and ADT at
the Dana-Farber/Brigham and Women’s Cancer Center from 2001–2013 for
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NCCN intermediate or high-risk prostate cancer and had archived formalin-
fixed paraffin-embedded tissue available. Twenty-six patients did not have
adequate tumor tissue for RNA extraction while 27 patients did not pass pre-
specified microarray quality control thresholds and were thus excluded from
analysis. GC scores were calculated for the remaining 100 patients,
consisting of 55 intermediate risk and 45 high-risk patients. Of note, the
clinical characteristics between those with adequate vs inadequate tissue for
analysis was similar except for a higher proportion of positive biopsy cores in
those with adequate tissue (median 50% vs 33%, Po0.001; Supplementary
Table 1). The duration of ADT was at the discretion of the treating physician,
and most (68%) received 6 months of ADT with a range of 3–39 months. The
ADT was typically started 2 months before the initiation of radiation.
Radiation was external beam alone for 97% of the patients to a median dose
of 72 Gy (range: 68.4–81.0 Gy). Included patients had all consented to a
prospective tissue collection protocol, and this study was approved by the
Dana-Farber/Harvard Cancer Center Institutional Review Board.
Specimen collection and processing
Six to ten 4 micron sections of the needle biopsy core with the highest
Gleason score and percentage of tumor involvement were macrodissected
for RNA extraction. GC scores were determined from the Decipher prostate
cancer classifier assay (GenomeDx Biosciences Laboratory, San Diego, CA,
USA) as previously described.4,5 Cancer of the Prostate Risk Assessment
(CAPRA) was calculated as previously described5 while substituting
pre-operative PSA with pre-radiation PSA. Risk categorization of GC and
CAPRA were based on prior publications.5,7,8 The primary end point of the
study was distant metastasis following radiation therapy. Secondary end
points evaluated were biochemical failure (nadir plus 2 definition) and
castrate resistance (defined as any rise in PSA despite being on salvage ADT
for biochemical failure).
Statistical analysis
Duration of ADT (⩽6 months vs 46 months), biopsy Gleason (⩽3+4 vs
⩾ 4+3) and clinical stage (oT2b vs ⩾ T2b) were treated as categorical
variables while age at radiation therapy (RT), pretreatment PSA (log 2
transformed), and percent positive cores were modeled as continuous
covariates. In time to event analyses, event times were defined as the time
from initiation of RT to metastases or date of last follow-up.
The performance of GC, CAPRA and NCCN risk categories were compared
and contrasted by measuring their ability to (1) independently predict
metastases using univariable (UVA) and multivariable (MVA) penalized Cox
regression;9 (2) discriminate risk among patients using survival receiver
operating characteristic curves and their respective c-indices;10 (3) exhibit
clinical usefulness by plotting out decision curves adapted to survival data;11
and (4) stratify metastatic risk using cumulative incidence curves12 based on
their previously published cutpoints. Least absolute shrinkage and selection
operator (LASSO) regression was a secondary penalized method used to
assess the relative importance of the variables of interest in predicting
metastasis. Furthermore, it has been demonstrated that LASSO regression
without penalization on the exposure variable produces an estimate of the
coefficient of the exposure variable of minimal bias with as few as three
events per variable.13 This method was also applied to the data. Confidence
intervals for survival c-indices were computed via the bootstrap. The
c-indices were considered statistically significant if the lower bound of the
95% confidence interval exceeded 0.50. The significance level was set at 0.05
for all tests while analyses were performed in R v3.0. With an anticipated
event rate of 0.13, this study had 80% power to detect a hazard ratio of 1.54
per 0.1 unit increase in continuous genomic biomarker score.
RESULTS
Patient characteristics
Patient characteristics are provided in Table 1. The median age of
patients in the study was 67 years (range, 45–87) and 16% of
patients were African–American. Thirty percent of patients had a
biopsy Gleason ⩽ 3+4, 36% had Gleason 4+3, and 34% of patients
had Gleason 8 or 9 disease. The median pretreatment PSA
was 7.3 ng ml−1 (interquartile range: 4.7–-14.9 ng ml−1) while the
median time between biopsy and radiation therapy was 4.5 months.
Sixty-eight percent of patients received 6 months of ADT, 1%
received 3 months of ADT, and the remaining 31% received
12–39 months of ADT. Eighty-seven percent received both
a gonadotropin-releasing hormone agonist and an anti-androgen.
The median follow-up on censored patients was 5.1 years
(interquartile range: 3.4-6.3) and 18 patients developed metastasis
during study follow-up. During this same period, 28 patients had
biochemical failure while 12 developed castrate resistant disease.
Calculation of GC and CAPRA scores
The distributions of GC and CAPRA scores are presented in
Figure 1. The median GC score for this biopsy-based cohort was
0.39 (interquartile range: 0.22–0.61). The median CAPRA score for
these patients was 5 (interquartile range: 4–6). We observed a
significant positive correlation between GC and biopsy Gleason
Table 1. Demographic and clinical characteristics of eligible patients
Variables Cohort
No. of patients (%) 100 (100%)
Patient age, year
Median (Range) 67 (47, 85)
IQR (Q1, Q3) 60–71
Race, n (%)
African–American 16 (16%)
Caucasian 79 (79%)
Other 5 (5%)
Pretreatment PSA (ng ml− 1)
Median (Range) 7.3 (1.5, 103)
IQR (Q1, Q3) 4.7–14.9
Biopsy gleason group, n (%)
⩽ 6 7 (7%)
7 (3+4) 23 (23%)
7 (4+3) 36 (36%)
8 15 (15%)
⩾ 9 19 (19%)
Clinical stage, n (%)
⩽ T2a 64 (64%)
⩾ T2b 35 (35%)
Tx 1 (1%)
Percent positive biopsy cores
Median (range) 50 (7.7, 100)
IQR (Q1, Q3) 33–75
NCCN risk category, n (%)
Intermediate 55 (55%)
High 45 (45%)
Time from biopsy to radiation therapy, months
Median (range) 4.5 (0.8, 25.7)
IQR (Q1, Q3) 4.0–5.5
Follow up of censored patients, year
Median (range) 5.1 (1.3, 11.9)
IQR (Q1, Q3) 3.4–6.3
Type of radiation therapy, n (%)
EBRT 97 (97%)
Brachy 1 (1%)
EBRT + Brachy 2 (2%)
Type of androgen deprivation therapy, n (%)
Bicalutamide 1 (1%)
Combined androgen blockade 87 (87%)
Leuprolide 12 (12%)
Abbreviations: EBRT, external beam radiation therapy; IQR, interquartile
range; NCCN, National Comprehensive Cancer Network.
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score (r= 0.38, Po0.001; Supplementary Figure 1) as well as
CAPRA scores (r= 0.37, Po0.001).
Ability of GC to predict for metastases and secondary end points
On UVA of baseline clinical and genomic risk factors we found
only GC was a significant predictor of metastasis, associated with a
40% increase in the risk of metastasis per 0.1 unit increase in score
(HR: 1.40; 95% confidence interval (CI): 1.10–1.84; P= 0.006;
Table 2). The CAPRA score had a hazard ratio of 1.15 per unit
increase but was not statistically significant (P= 0.271). Likewise,
NCCN high-risk (ref: intermediate risk) was not significantly
predictive of metastasis (HR: 2.00; 95% CI: 0.78-5.35; P= 0.147).
Figure 1. Distributions of the study cohort by (a) Cancer of the Prostate Risk Assessment (CAPRA), (b) genomic classifier risk scores.
Table 2. Results of cox proportional hazards analysis of GC, clinical risk factors and CAPRA
Variables UVA MVA
HR 95% LB 95% UB P-value HR 95% LB 95% UB P-value
Model I Age at radiation therapy, year 1.05 0.98 1.12 0.185 1.03 0.95 1.11 0.484
Log2 pretreatment PSA 1.36 0.88 2.09 0.164 1.26 0.78 2.04 0.343
ADT duration 4 6 months 1.18 0.42 3.01 0.741 1.18 0.30 4.47 0.812
Biopsy gleason ⩾ 4+3 2.24 0.77 8.67 0.149 1.34 0.41 5.49 0.643
Clinical stage ⩾ T2b 0.58 0.18 1.58 0.298 0.71 0.19 2.37 0.585
Percent positive coresa 0.99 0.97 1.01 0.335 0.99 0.96 1.01 0.181
Biopsy deciphera 1.40 1.10 1.84 0.006 1.36 1.04 1.83 0.024
Model II CAPRAb 1.15 0.90 1.51 0.271 0.96 0.70 1.31 0.777
Biopsy deciphera 1.40 1.10 1.84 0.006 1.44 1.08 1.98 0.012
Model III NCCN high 2.00 0.78 5.35 0.147 1.11 0.42 2.99 0.839
Biopsy deciphera 1.40 1.10 1.84 0.006 1.37 1.06 1.78 0.014
Model IV Biopsy gleason ⩾ 4+3 2.24 0.77 8.67 0.149 1.53 0.50 6.19 0.480
Biopsy deciphera 1.40 1.10 1.84 0.006 1.32 1.03 1.73 0.025
Abbreviations: ADT, androgen deprivation therapy; CAPRA, Cancer of the Prostate Risk Assessment; GC, genomic classifier; HR, hazard ratio; LB, lower bound;
MVA, multivariable analysis; NCCN, National Comprehensive Cancer Network; UB, upper bound; UVA, univariable analysis. aHRs reported per 10% increase.
bHRs reported per 1 unit increase.
Table 3. LASSO regression hazard ratios for GC and clinical risk factors using a penalty parameter optimized via cross-validation
Variables LASSO with penalization on all variables LASSO without penalization on biopsy decipher
Order of entry into LASSO model HR using optimized penalty of 0.049
Age at radiation therapy, years 6 NA
Log2 pretreatment PSA 5 NA
ADT duration 4 6 months 7 NA
Biopsy gleason ⩾ 4+3 4 NA
Clinical stage ⩾ T2b 3 0.98
Percent positive coresa 2 0.95
Biopsy deciphera 1 1.44
Abbreviations: ADT, androgen deprivation therapy; GC, genomic classifier; HR, hazard ratio; LASSO, least absolute shrinkage and selection operator; NA, not
applicable. aHRs reported per 10% increase.
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When adjusting for relevant clinical variables in MVA including
stage, Gleason, PSA, percent of positive cores, duration of ADT and
year of treatment, we observed a small reduction in the GC hazard
ratio (HR: 1.36; 95% CI: 1.04–1.83) but it remained a significant
predictor of metastasis (P= 0.024). LASSO regression established
that GC was the most important variable in predicting metastasis
as it was the first variable to enter the model followed by percent
of positive biopsy cores with age at RT being the last and,
therefore, least important variable (Table 3; Figure 2a). LASSO
regression without penalizing GC, but with a cross-validated
Figure 2. (a) Least absolute shrinkage and selection operator (LASSO) coefficient path demonstrating the order of importance of genomic
classifier (GC) and clinical variables in predicting metastasis. Moving from right to left, the order of nonzero hazards coefficients represents the
order of variable importance. (b) LASSO coefficient path without penalization on GC using a cross-validated penalty parameter of 0.049,
represented by a vertical dashed line. Only GC, percent of positive cores and clinical stage have nonzero hazards coefficients at this level of
penalization. This model estimates a less biased hazard ratio for GC when the number of events per variable is low. (c) Survival c-indices at 5
years following radiation therapy (RT) for GC, Cancer of the Prostate Risk Assessment (CAPRA) and National Comprehensive Cancer Network
(NCCN) risk. (d) Decision curve analysis comparing net benefit at 5 years post-RT of GC and CAPRA across various threshold probabilities.
Compared with ‘treat none’ and ‘treat all’ scenarios (in which no risk prediction model is employed) to make treatment decisions, across a
range of threshold probabilities GC had the highest net benefit compared with the clinical-only CAPRA risk model. The net benefit is defined
as a measure of the relative value of benefits from identifying higher risk men that should for example, receive more intensive therapy (for
example, longer duration hormonal suppression) and harms (for example, morbidity of long-term androgen deprivation therapy (ADT))
associated with the GC and CAPRA risk models.
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penalty parameter of 0.049 on all other variables, produced a
hazard ratio for GC of 1.44 (Table 3; Figure 2b), closely
corroborating the results from MVA.
In a separate MVA that included both GC and CAPRA, as well as
one that included GC and NCCN risk, GC’s independent predictive
capability was consistent across models with HR’s of 1.44
(p = 0.012) and 1.37 (p = 0.014), respectively. Neither CAPRA nor
NCCN were significant predictors in these models and each saw a
large variance in their hazard ratios when compared with their
UVA results. Similar results were observed when GC was modeled
with biopsy Gleason score (Table 2).
Cox regression analysis on secondary end points demonstrated
that only CAPRA was a significant predictor of biochemical failure
on UVA (HR: 1.23; 95% CI: 1.01-1.49; P= 0.042; Supplementary
Table 2) but neither of the models were significant predictors on
MVA. With respect to the development of castrate resistant
disease, GC was a significant predictor on UVA as well as after
adjusting for NCCN risk (HR for GC: 1.43; 95% CI: 1.01-2.09;
P= 0.044) and for CAPRA (HR for GC: 1.48; 95% CI: 1.00–2.45;
P= 0.049; Supplementary Table 3).
We next evaluated the discrimination performance of GC, which
had a survival c-index at 5 years following RT for predicting
metastasis of 0.76 (95% CI: 0.57–0.89; Figure 2c). This compared
favorably to a c-index of 0.45 for CAPRA (95% CI: 0.27–0.64) and
0.63 for NCCN (95% CI: 0.40–0.78), as only the GC’s c-index
confidence interval did not contain 0.5. The c-index showed
Figure 3. (a) Cumulative incidence curves in which patients are stratified by National Comprehensive Cancer Network (NCCN) risk categories.
(b) Cumulative incidence curves in which patients are stratified by Cancer of the Prostate Risk Assessment (CAPRA) risk categories.
(c) Cumulative incidence curves in which patients are stratified by genomic classifier (GC) risk categories. (d) Cumulative incidence curves in
which patients are stratified by GC risk using an exploratory cutoff of 0.2. RT, radiation therapy.
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consistent discrimination by GC over time, as the c-index of GC for
predicting metastasis at 10 years following RT was 0.78 (95% CI:
0.60–0.87; Supplemental Figure 2). Decision curve analysis also
demonstrated that the net benefit of using GC for treatment
decisions was generally higher than basing clinical decisions on
either the CAPRA risk model or naively choosing to either treat all
patients or to treat none (Figure 2d). Therefore, irrespective of the
threshold probability for making a treatment decision based on
the GC risk model, decision curve analysis shows that using GC will
improve decision-making.
Metastatic risk stratification
When studying risk stratification, there was not a significant
difference in the cumulative incidence of metastasis between
NCCN high and intermediate patients (P= 0.238; Figure 3). CAPRA
appeared to stratify risk better but the differences were not
statistically significant (P= 0.215). However, pre-determined GC
risk groups showed a significant ability to stratify patient risk
of metastasis, with the 26% of patients in the high genomic
risk group (GC40.6) experiencing a 5-year cumulative risk of
metastasis of 20% after radiation and ADT (P= 0.02). The low
and intermediate genomic risk group curves overlapped
beyond 5 years as the number of patients at risk within each
group dropped substantially thereafter. In exploratory analysis, we
found that patients with a GC score ⩽ 0.2 had a 0% cumulative
incidence of metastasis throughout the period of follow-up
(P= 0.07).
DISCUSSION
To the best of our knowledge, this study of contemporary
intermediate and high-risk patients treated with radiation and a
median of 6 months of ADT is the first to demonstrate that a
biopsy-based 22-gene GC can predict for distant metastases after
definitive radiation and ADT. We found that the GC outperformed
clinical variables and accurately predicted the 5-year risk of distant
metastases with a c-Index of 0.76. In addition, while this study
contained mostly men with intermediate risk disease, the 26%
with a high GC score (40.6) had a 5-year risk of distant metastasis
of 20% despite treatment with both radiation and ADT.
The clinical implication of this study is that the GC, which
was developed on men treated with prostatectomy, may be
used to accurately risk-stratify men for metastatic failure after
radiation and ADT. For the 26 percent of men with a high GC
score, there was a high-risk of metastases at 5 years despite
radiation and ADT, and these men may need to consider
treatment intensification, such as with longer duration ADT which
has been shown to improve survival for locally advanced
disease,14,15 or with docetaxel which has shown early promise in
the initial report of RTOG 05-21 (ref. 16), or with entry into a trial
of novel therapies for aggressive prostate cancer. Dose was not
predictive of metastasis in this cohort, and whether further
radiation dose intensification could benefit men with a high GC
score remains unknown. Conversely, for the 28% of men who had
a GC score ⩽ 0.2, the risk of metastases appeared to be very low.
While this cutpoint was exploratory and will need validation
before being considered for clinical use, it raises the possibility
that sometime in the future, given the lack of development of
metastases in these men, and the increasing recognition of the
harms of ADT,17,18 men with a GC score ⩽ 0.2 may be reasonable
candidates for forgoing ADT and choosing dose-escalated
radiation alone, which is currently an NCCN-endorsed option for
some men with intermediate and even select men with high-risk
disease.1
Although further studies in larger data sets will be needed to
validate the risk-adapted treatment paradigm described above,
this study highlights the significant value that GCs may have for
patients who choose radiation as primary management of their
prostate cancer. The GC outperformed clinical variables in
predicting for distant metastasis, and this may reflect the fact
that the classifier is able to measure multiple pathways at once,
including information about androgen signaling, cell-cycle pro-
gression and chromosome structure maintenance.19 Another
advantage of the GCs is that they are reproducible lab-based
assays that do not depend on institutional expertize, as opposed
to Gleason grading, which can be highly variable depending on
the expertize of the reading pathologist.20,21 Finally, recent data
suggests that GCs may also have the advantage of being less
sensitive to sampling error.2
Work by Freedland et al.22 has also highlighted the potential
value of genomics in radiation-managed men. In their study of
147 radiation-managed men of whom about half received ADT
and half did not, a 33 gene classifier based on cell-cycle
progression (Myriad) was associated with the risk of biochemical
failure after radiation. It was also associated with the risk of
prostate-cancer mortality, although the number of events was
small at 6. Our study, which uses a different GC, adds to this
literature by focusing exclusively on men treated with both
radiation and ADT, and emphasizing the highly clinically
significant end point of distant metastasis. This has allowed us
to identify a subgroup representing 26% of the men who remain
at high-risk of distant metastasis despite treatment both with
radiation and ADT and, therefore, need consideration of even
further treatment intensification.
A limitation of the current study is the size of the data set and
length of follow-up, and so further studies will be needed to
validate these findings in larger data sets with longer follow-up. In
addition, the hypothesis that patients with very low GC score ⩽ 0.2
may be able to omit ADT requires further testing in previously
treated cohorts as well as in prospective studies, which are
currently being planned. Finally, while the GC score was
prognostic for distant metastasis, it did not have a significant
association with biochemical recurrence. This may reflect the fact
that the test was originally developed to specifically predict for
distant metastasis and generally only a minority of biochemical
recurrences will lead to distant metastasis. Another consideration
is that none of the patients in this study received a multi-
parametric magnetic resonance imaging, and it has previously
been shown that magnetic resonance imaging can add some
prognostic information to clinical variables through upstaging or
through detecting potentially higher grade lesions.23 Future
studies should evaluate how GC adds to prognostic value when
multiparametric magnetic resonance imaging has also been
performed,24 although studies with the cell-cycle progression
score suggest that the magnetic resonance imaging and the
genomic information are capturing different types of prognostic
information.25
CONCLUSION
In summary, this is the first report of the ability of a 22-gene
biopsy-based GC to accurately predict distant metastasis in men
with intermediate or high-risk prostate cancer treated with
radiation and a median of 6 months of ADT. Patients with the
highest GC risk (GC40.6) had high rates of metastasis despite
multi-modal therapy and could potentially be candidates for
intensification of therapy and/or entry into clinical trials of novel
therapy.
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